Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.53 |
| ▸ | CTSK | P43235 | 8/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19969242 | 1.00 | CTSS (0.53) | CTSSCTSKACECTSBCTSL | |
| SCHEMBL18180261 | 0.89 | CTSS (0.46) | CTSSCTSKACECTSBCTSL | |
| SCHEMBL18180278 | 0.89 | CTSS (0.47) | CTSSCTSKACECTSBCTSL | |
| SCHEMBL18317296 | 0.89 | CTSS (0.46) | CTSSCTSKACECTSBCTSL | |
| SCHEMBL19962117 | 0.89 | CTSS (0.46) | CTSSCTSKACECTSBCTSL | |
| SCHEMBL19969174 | 0.89 | CTSS (0.60) | CTSSCTSKACECTSBCTSL | |
| SCHEMBL18057248 | 0.89 | CTSS (0.60) | CTSSCTSKACECTSBCTSL | |
| SCHEMBL18317994 | 0.89 | CTSS (0.46) | CTSSCTSKACECTSBCTSL | |
| SCHEMBL18181211 | 0.89 | CTSS (0.48) | CTSSCTSKACECTSBCTSL | |
| SCHEMBL18181048 | 0.89 | CTSS (0.46) | CTSSCTSKACECTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| WO-2016172425-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE (NO.5) LIMITED (GB) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | CTSS 2266/4885CTSK 3289/4885ACE 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.